{"id":"ha-0-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or discomfort"},{"rate":null,"effect":"Transient blurred vision (if ophthalmic)"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL1564377","moleculeType":"Small molecule","molecularWeight":"116.12"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hyaluronic acid (HA) is a naturally occurring polysaccharide that binds water and maintains tissue hydration and elasticity. When formulated at 0.3% concentration, it is used to restore moisture, reduce friction, and support tissue integrity in affected areas. The mechanism relies on HA's hygroscopic properties and its role in maintaining the extracellular matrix.","oneSentence":"HA 0.3% is a hyaluronic acid-based topical or injectable formulation that provides hydration, lubrication, and tissue support through its viscoelastic properties.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:36.313Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye syndrome or ocular surface disease (if ophthalmic formulation)"},{"name":"Wound healing or skin hydration (if dermatologic formulation)"}]},"trialDetails":[{"nctId":"NCT06388070","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2024-05-20","conditions":"Dry Eye Syndromes","enrollment":297},{"nctId":"NCT07265778","phase":"NA","title":"Clinical Investigation for Evaluating the Safety and Efficacy of JTM102 to Mid Face Volume Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jetema Co., Ltd.","startDate":"2024-10-22","conditions":"Mid Face Volume Deficit","enrollment":149},{"nctId":"NCT07162610","phase":"NA","title":"Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaResearch Co.,Ltd","startDate":"2024-04-07","conditions":"Mid-face Volume Deficit","enrollment":89},{"nctId":"NCT06777199","phase":"NA","title":"A Comparative Study of Selective Dorsal Neurectomy, Pulsed Radiofrequency Neuromodulation, and Intragranular Hyaluronic Acid Injection for Premature Ejaculation","status":"COMPLETED","sponsor":"Ahmed Hamdy Ahmed","startDate":"2022-07-01","conditions":"Premature Ejaculation","enrollment":30},{"nctId":"NCT05386030","phase":"PHASE3","title":"Saypha® VOLUME Lidocaine for Midface Augmentation","status":"COMPLETED","sponsor":"Croma-Pharma GmbH","startDate":"2022-08-16","conditions":"Moderate to Severe Midface Volume Deficit","enrollment":562},{"nctId":"NCT06209879","phase":"PHASE4","title":"Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-02-05","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03353389","phase":"","title":"Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang","status":"COMPLETED","sponsor":"Selayang Hospital","startDate":"2017-11-01","conditions":"Acute Kidney Injury, Acute Renal Failure, Kidney Failure, Acute","enrollment":170000},{"nctId":"NCT04830020","phase":"PHASE2","title":"Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2021-02-26","conditions":"Covid19","enrollment":180},{"nctId":"NCT03281486","phase":"NA","title":"\"Hyaluronan\" Formulation for Type 2 Diabetic Patients With Dry Mouth","status":"COMPLETED","sponsor":"You First Services","startDate":"2018-01-28","conditions":"Dry Mouth, Xerostomia, Type 2 Diabetics","enrollment":30},{"nctId":"NCT01529203","phase":"PHASE3","title":"Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-02","conditions":"Aging","enrollment":60},{"nctId":"NCT04174131","phase":"PHASE3","title":"Restylane + Lidocaine and Restylane Lyft for the Treatment of Nasolabial Folds","status":"COMPLETED","sponsor":"Erevna Innovations Inc.","startDate":"2019-11-13","conditions":"Wrinkles Such as Nasolabial Folds","enrollment":10},{"nctId":"NCT02674880","phase":"PHASE2","title":"Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2016-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":41},{"nctId":"NCT02703740","phase":"NA","title":"Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds","status":"COMPLETED","sponsor":"Laboratoires Genévrier","startDate":"2016-01-11","conditions":"Aesthetics","enrollment":60},{"nctId":"NCT03833687","phase":"NA","title":"Aesthetic Performance of an Injective Treatment for the Skin Roughness and Laxity of Inner Arm and Abdomen","status":"COMPLETED","sponsor":"Derming SRL","startDate":"2018-09-11","conditions":"Skin Flaccidity and Roughness of the Abdomen and Inner Arms","enrollment":24},{"nctId":"NCT03295019","phase":"NA","title":"\"Hyaluronan\" Formulation for Dry Mouth in Sleep Apnea Patients","status":"UNKNOWN","sponsor":"You First Services","startDate":"2017-08-04","conditions":"Dry Mouth, Xerostomia, OSA","enrollment":45},{"nctId":"NCT02195427","phase":"NA","title":"TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds","status":"COMPLETED","sponsor":"Teoxane SA","startDate":"2014-06","conditions":"Nasolabial Folds, Wrinkles","enrollment":148},{"nctId":"NCT02253147","phase":"NA","title":"TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds","status":"COMPLETED","sponsor":"Teoxane SA","startDate":"2014-09","conditions":"Nasolabial Folds, Wrinkles","enrollment":140},{"nctId":"NCT00730457","phase":"PHASE1","title":"Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine","status":"COMPLETED","sponsor":"VaxInnate Corporation","startDate":"2008-07","conditions":"Influenza","enrollment":56},{"nctId":"NCT01623232","phase":"PHASE1, PHASE2","title":"MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2012-10","conditions":"Influenza Vaccines, Aged","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HA 0.3%","genericName":"HA 0.3%","companyName":"Huons Co., Ltd.","companyId":"huons-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HA 0.3% is a hyaluronic acid-based topical or injectable formulation that provides hydration, lubrication, and tissue support through its viscoelastic properties. Used for Dry eye syndrome or ocular surface disease (if ophthalmic formulation), Wound healing or skin hydration (if dermatologic formulation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}